Cover Image
市場調查報告書

Safinamide(精神分裂症治療藥):市場預測與分析

Safinamide (Parkinson's Disease) - Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 217361
出版日期 內容資訊 英文 87 Pages
訂單完成後即時交付
價格
Back to Top
Safinamide(精神分裂症治療藥):市場預測與分析 Safinamide (Parkinson's Disease) - Forecast and Market Analysis to 2022
出版日期: 2014年03月31日 內容資訊: 英文 87 Pages
簡介

2012年Newron完成臨床實驗第三階段的safinamide。safinamide是具有雙重結構的α氨基酸衍生物,具有MAO-B和谷氨酸釋放抑製劑的作用(EPDA,新聞稿,2012年4月14日)。2006年,Merck Serono(Merck KGaA的一個部門)取得了safinamido的全球壟斷權,但2011年開發中止,Merck由於對今後的市場規模有所疑慮而歸還了safinamide的相關權利。

本報告提供精神分裂症治療藥的治療藥之一──safinamide的全球市場相關分析,提供疾病概要和治療方法,safinamide的商品資訊(特色·功效·安全性等)和競爭力,競爭的企業·藥品概要,市場機會及未滿足需求,臨床實驗的進展,全球主要國家的市場販售額預測(今後10年份)等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因與病情
    • 病因
    • 病理生理學
    • 預測
    • QoL(生活品質)
  • 症狀

第4章 疾病管理

  • 概要
    • 診斷:The UK Brain Bank的評估標準
    • 治療指南與主要的處方藥
  • 治療方法概要
    • 多巴胺有作用之等級
    • 帕金森氏症的各階段治療方法
    • 其他治療選擇
  • 帕金森氏症的評估規模
    • 帕金森氏症統一規模(UPDRS)
    • Hoehn and Yahr的病期分類
    • 其他臨床評估方法

第5章 競爭企業的評估

  • 概要
  • 競爭企業的策略性評估

第6章 市場機會及未滿足需求

  • 概要
  • 運動併發症的治療:Dyskinesias and OFF Episodes
    • 未滿足需求
    • 差距分析
    • 市場機會
  • 非運動併發症·癡呆的治療
  • 神經保護劑/疾病緩和劑
  • 改良的製劑
  • 可靠性高的生物標記之識別
  • 改善臨床實驗的設計

第7章 開發平台評估

  • 概要
  • 臨床實驗階段有潛力的醫藥品

第8章 關於Safinamide

  • 概要
  • 功效
  • 安全性
    • 給藥·劑型方法
    • 在臨床方面的潛在性地位
    • 在商業方面的潛在性地位
    • 價格設定和醫療費給付
  • SWOT分析
  • 預測

第9章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC398DFR

Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

In 2012, Newron completed Phase III clinical trials for safinamide, a dual-mechanism a-aminoamide derivative, acting as an MAO-B and glutamate release inhibitor (EPDA, press release, May 14, 2012). In 2006, Merck Serono (a division of Merck KGaA) had acquired the exclusive worldwide rights for safinamide; however, in 2011 the deal was terminated, seeing Merck returning the compound to Newron due to concerns over the potential market size for the drug.

Scope

  • Overview of Parkinson's disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Safinamide including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Safinamide for the top seven countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Brazil.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Parkinson's disease
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Safinamide performance
  • Obtain sales forecast for Safinamide from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Brazil).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Overview
    • 4.1.1. Diagnosis - The UK Brain Bank Criteria
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
  • 4.2. Treatment Synopsis
    • 4.2.1. Dopaminergic Therapy Classes
    • 4.2.2. Treatment of Parkinson's Disease by Stage
    • 4.2.3. Other Treatment Options
  • 4.3. Parkinson's Disease Assessment Scales
    • 4.3.1. Unified Parkinson's Disease Rating Scale (UPDRS)
    • 4.3.2. Hoehn and Yahr Clinical Staging
    • 4.3.3. Other Clinical Assessments

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Treatment of Motor Complications - Dyskinesias and OFF Episodes
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Treatment of Non-Motor Symptoms and Dementia
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Neuroprotective/Disease-Modifying Agents
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Improved Drug Formulations
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Identification of Reliable Biomarkers
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Improved Clinical Trial Design
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development

8. Safinamide

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical Positioning
  • 8.6. Potential Commercial Positioning
  • 8.7. Pricing and Reimbursement
  • 8.8. SWOT Analysis
  • 8.9. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Parkinson's Disease Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Compliance Assumptions
    • 9.4.5. Individual Drug Assumptions
    • 9.4.6. Generic Erosion
    • 9.4.7. Pricing of Pipeline Agent
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6 About the Authors
    • 9.6.1. Author
    • 9.6.2. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Parkinson's Disease
  • Table 2: UK Brain Bank Diagnostic Criteria
  • Table 3: Diagnosis and Treatment Guidelines for Parkinson's Disease
  • Table 4: Most Prescribed Drugs for Parkinson's Disease by Class in the Global Markets, 2014
  • Table 5: Dopaminergic Therapy in Parkinson's Disease
  • Table 6: UPDRS Clinical Assessment of Disease Severity
  • Table 7: Parkinson's Disease Assessment Scales Used in Clinical Trials
  • Table 8: Treatment of Motor Symptoms in Parkinson's Disease
  • Table 9: Leading Treatments for Parkinson's Disease, 2014
  • Table 10: Unmet Need and Opportunity in Parkinson's Disease
  • Table 11: Dyskinesia Pipeline, 2014
  • Table 12: Dementia Pipeline, 2014
  • Table 13: Parkinson's Disease-Modifying Therapeutics Pipeline, 2014
  • Table 14: Product Profile - Safinamide
  • Table 15: Summary of Relevant Clinical Trials for Safinamide
  • Table 16: Safinamide SWOT Analysis, 2014
  • Table 17: Global Sales Forecasts ($m) for Safinamide, 2012-2022

List of Figures

  • Figure 1: Overview - L-dopa Metabolism and Inhibitor Classes
  • Figure 2: Overview - Treatment of Motor Symptoms of Parkinson's Disease
  • Figure 3: Pharmacokinetics of Levodopa
  • Figure 4: Parkinson's Disease - Phase II-III Pipeline, Segmented by Indication, 2014
  • Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in Parkinson's Disease, 2012-2022
Back to Top